ArticleInternational journal of women's dermatology2026
Noninvasive physical plasma in vulvar lichen sclerosus: a prospective pilot study.
Article in International journal of women's dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lichen sclerosus (LS) is a chronic inflammatory dermatosis predominantly affecting the anogenital region and is associated with significant impairment of quality of life. High-potency topical corticosteroids are the standard of care; however, some patients show inadequate response or experience relapse. Noninvasive physical plasma (NIPP) is an emerging therapeutic modality with antimicrobial and anti-inflammatory properties, but its role in LS remains unclear. Objective: To evaluate the safety, tolerability, and preliminary efficacy of NIPP as an adjunctive treatment in patients with vulvar LS refractory to topical corticosteroids. Methods: This prospective single-arm pilot study included 5 women with histologically confirmed LS and/or chronic vulvar inflammation with persistent symptoms despite topical corticosteroid therapy. Patients received at least 3 NIPP sessions (plasma care, terraplasma medical GmbH), each applied for 1 minute over a 4 × 4 cm area at intervals of 4 to 6 weeks, while continuing standard topical treatment. Clinical assessment, photographic documentation, and patient-reported outcomes using a study-specific questionnaire were collected at baseline, at each session, and at follow-up 4 to 6 weeks after the final treatment. Results: The median age was 46 years, and the median disease duration was 3 years. No consistent improvement in symptoms or clinical findings was observed following NIPP treatment. Three patients indicated willingness to undergo NIPP again, and 1 patient reported improvement in sexual well-being. No severe adverse events occurred. Treatment was generally well tolerated; however, 1 patient discontinued participation due to treatment-related discomfort. Limitations: The main limitations are small sample size, lack of a control group, and heterogeneity in disease duration and prior/current treatments. Conclusion: In this pilot study, adjunctive NIPP did not demonstrate consistent clinical benefit in vulvar LS but appeared safe and well-tolerated. Larger controlled studies are required to further assess its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.